Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

K Fousek, LA Horn, C Palena - Pharmacology & therapeutics, 2021 - Elsevier
Tumor progression relies on the ability of cancer cells to effectively invade surrounding
tissues and propagate. Among the many mechanisms that contribute to tumor progression is …

Tumor plasticity and resistance to immunotherapy

LA Horn, K Fousek, C Palena - Trends in cancer, 2020 - cell.com
Tumor cell plasticity exhibited as an epithelial–mesenchymal transition (EMT) has been
identified as a major obstacle for the effective treatment of many cancers. This process …

The evolution of T-cell therapies for solid malignancies

K Fousek, N Ahmed - Clinical Cancer Research, 2015 - AACR
Primary resistant, recurrent, and relapsed solid tumors are often nonresponsive to
conventional antineoplastic therapies. Moreover, in responsive tumors, the therapeutic-to …

[HTML][HTML] Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

M Hegde, M Mukherjee, Z Grada… - The Journal of …, 2016 - Am Soc Clin Investig
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence
after treatment with CAR T cells that are redirected to single tumor antigens. Given the …

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

K Bielamowicz, K Fousek, TT Byrd, H Samaha… - Neuro …, 2018 - academic.oup.com
Background Glioblastoma (GBM) is the most common primary malignant brain cancer, and
is currently incurable. Chimeric antigen receptor (CAR) T cells have shown promise in GBM …

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

LK Donovan, A Delaidelli, SK Joseph, K Bielamowicz… - Nature medicine, 2020 - nature.com
Recurrent medulloblastoma and ependymoma are universally lethal, with no approved
targeted therapies and few candidates presently under clinical evaluation. Nearly all …

[HTML][HTML] CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

K Fousek, J Watanabe, SK Joseph, A George, X An… - Leukemia, 2021 - nature.com
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in
treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients …

[HTML][HTML] Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication

LA Horn, PL Chariou, SR Gameiro… - The Journal of …, 2022 - Am Soc Clin Investig
Collagens in the extracellular matrix (ECM) provide a physical barrier to tumor immune
infiltration, while also acting as a ligand for immune inhibitory receptors. Transforming …

TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer

TT Byrd, K Fousek, A Pignata, C Szot, H Samaha… - Cancer research, 2018 - AACR
Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In
this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a …

[HTML][HTML] Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

LA Horn, J Riskin, HA Hempel, K Fousek… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Despite the success of immune checkpoint blockade therapy in the treatment of
certain cancer types, only a small percentage of patients with solid malignancies achieve a …